Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
about
Sirtuins in Skin and Skin Cancers.Robo3A and Robo3B expression is regulated via alternative promoters and mRNA stability.Galectin-3 sensitized melanoma cell lines to vemurafenib (PLX4032) induced cell death through prevention of autophagy.Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas.
P2860
Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Vemurafenib: First-in-Class BR ...... ectable or Metastatic Melanoma
@ast
Vemurafenib: First-in-Class BR ...... ectable or Metastatic Melanoma
@en
Vemurafenib: First-in-Class BR ...... ectable or Metastatic Melanoma
@nl
type
label
Vemurafenib: First-in-Class BR ...... ectable or Metastatic Melanoma
@ast
Vemurafenib: First-in-Class BR ...... ectable or Metastatic Melanoma
@en
Vemurafenib: First-in-Class BR ...... ectable or Metastatic Melanoma
@nl
prefLabel
Vemurafenib: First-in-Class BR ...... ectable or Metastatic Melanoma
@ast
Vemurafenib: First-in-Class BR ...... ectable or Metastatic Melanoma
@en
Vemurafenib: First-in-Class BR ...... ectable or Metastatic Melanoma
@nl
P2860
P3181
P1476
Vemurafenib: First-in-Class BR ...... ectable or Metastatic Melanoma
@en
P2093
Danielle Roman
Lindsay Shelledy
P2860
P3181
P356
10.6004/JADPRO.2015.6.4.6
P407
P577
2015-01-01T00:00:00Z